BETA: Please send your feedback!
Xencor
XNCR:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
About
Biotechnology
Founded 1997
Xencor, Inc. is a clinical stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases, asthma & allergic diseases and cancer. Its clinical sate XmAb technology is used for the treatment of IgG4-related disease; systemic lupus erythematosus; asthma & allergic diseases; acute myeloid leukemia; B-cell malignancies; and neuroendocrine tumors. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| Bruce Leonard Andrews Carter, PhD | Chairman | Male |
| Bassil I. Dahiyat, PhD | President, Chief Executive Officer & Director | Male |
| John J. Kuch, CPA | Secretary & Vice President-Finance | Male |
| John R. Desjarlais, PhD | Chief Scientific Officer & Senior VP-Research | Male |
| Paul A. Foster, MD | Chief Medical Officer & Senior Vice President | Male |
| Stephen L. Mayo, PhD | Founder | Male |
| Mark W. Lotz | Vice President-Regulatory Affairs | Male |
Mindful Investing Summary
Xencor - Competitors and Related Companies
How Xencor stacks up to its peers in the Biotechnology industry or with competing business segments.
Xencor
XNCR:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
MacroGenics
MGNX:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
Alexion Pharmaceuticals
ALXN:NAS
Biotechnology
—
LARGE cap
(—)
—
since start of 2022
—
Amgen
AMGN:NAS
Biotechnology
—
MEGA cap
(—)
—
since start of 2022
—
Johnson & Johnson
JNJ:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2022
—
Merck
MRK:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2022
—